How It Works
TB-500 is a synthetic version of the active region of Thymosin Beta-4 (TB4), a 43-amino-acid protein that is naturally produced by the thymus gland and found in virtually all human cells. Thymosin Beta-4 is one of the most abundant intracellular proteins and plays critical roles in tissue repair, cell migration, and wound healing.
The primary mechanism of TB-500 involves binding to and sequestering actin — a key structural protein in cells. By regulating actin polymerization, TB-500 promotes cell migration, allowing repair cells to reach injured tissue more effectively. It also upregulates integrin-linked kinase (ILK), which promotes cell survival and migration, and stimulates angiogenesis — the formation of new blood vessels — which is essential for delivering nutrients and oxygen to healing tissue.
TB-500's small molecular size gives it high systemic bioavailability, meaning it can travel through the bloodstream to reach distant injury sites regardless of injection location. This distinguishes it from BPC-157, which is often injected locally near the injury. Research has shown particular promise in cardiac repair, corneal healing, and musculoskeletal tissue recovery.
Benefits
- Promotes cell migration to injury sites — through actin regulation and ILK activation
- Stimulates angiogenesis — new blood vessel formation at sites of injury
- Reduced inflammation — anti-inflammatory effects in damaged tissues
- Cardiac repair potential — demonstrated in myocardial infarction animal models
- Systemic bioavailability — does not need to be injected near the injury site
- Synergistic with BPC-157 — commonly stacked for enhanced healing effects
Side Effects
- Generally well-tolerated with a favorable safety profile in available research
- Injection site reactions — redness, mild pain, bruising (common)
- Head rush or lightheadedness — occasionally reported shortly after injection
- Mild lethargy — transient fatigue reported by some users during loading phase
- Temporary hair growth — anecdotally reported (related to TB4's role in hair follicle development)
- No significant organ toxicity documented in published literature
- Theoretical concern about promoting growth in existing cancers (not observed in research)
Dosing Protocol
| Parameter | Details |
|---|---|
| Loading Phase | 2-2.5mg every other day for 4-6 weeks |
| Maintenance Phase | 2-2.5mg once or twice monthly |
| Administration | Subcutaneous injection (any location — systemic distribution) |
| Cycle Length | 6-12 weeks total (loading + maintenance) |
| Common Stack | BPC-157 250-500mcg 2x daily (injected near injury site) |
What You Will Need
- TB-500 lyophilized vial (typically 2mg or 5mg)
- Bacteriostatic water (30mL)
- Insulin syringes (1mL, 29-31ga)
- Alcohol swabs
- Sharps container